KalVista Pharmaceuticals (NASDAQ:KALV) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• KalVista Pharmaceuticals has earned a "Sell (D-)" rating from Weiss Ratings, reflecting concerns about the company's performance and outlook.
• Despite the negative rating, other analysts have issued a range of positive ratings, with a consensus price target of $26.43 and one analyst issuing a "Strong Buy" rating.
• KalVista’s recent quarterly earnings report revealed a loss of ($1.12) EPS, missing analyst expectations, with revenues of $1.43 million compared to forecasts of $1.97 million.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

KALV has been the topic of a number of other reports. HC Wainwright raised their price objective on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Leerink Partners increased their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, July 7th. JMP Securities raised their price target on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a "market outperform" rating in a report on Friday, September 12th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, September 12th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $26.43.

KalVista Pharmaceuticals Stock Up 5.2%

NASDAQ:KALV opened at $11.49 on Wednesday. The company has a market cap of $580.47 million, a P/E ratio of -2.92 and a beta of -0.15. The firm's 50 day moving average is $13.19 and its two-hundred day moving average is $12.87. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.21). The firm had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.97 million. Research analysts forecast that KalVista Pharmaceuticals will post -3.56 earnings per share for the current fiscal year.

Insider Activity at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 10,940 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $144,626.80. Following the transaction, the chief executive officer directly owned 386,858 shares of the company's stock, valued at approximately $5,114,262.76. The trade was a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Paul K. Audhya sold 2,942 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.22, for a total transaction of $38,893.24. Following the completion of the transaction, the insider owned 119,841 shares of the company's stock, valued at $1,584,298.02. This trade represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,856 shares of company stock worth $374,910 over the last three months. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its position in shares of KalVista Pharmaceuticals by 3.4% during the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company's stock worth $611,000 after acquiring an additional 1,762 shares during the last quarter. GAMMA Investing LLC grew its stake in KalVista Pharmaceuticals by 567.3% during the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after purchasing an additional 3,767 shares in the last quarter. Invesco Ltd. increased its holdings in KalVista Pharmaceuticals by 154.5% during the 1st quarter. Invesco Ltd. now owns 39,804 shares of the specialty pharmaceutical company's stock worth $459,000 after purchasing an additional 24,164 shares during the last quarter. Woodline Partners LP raised its position in shares of KalVista Pharmaceuticals by 25.5% in the 1st quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company's stock valued at $18,666,000 after purchasing an additional 329,068 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of KalVista Pharmaceuticals by 2.8% in the 1st quarter. Wellington Management Group LLP now owns 126,268 shares of the specialty pharmaceutical company's stock valued at $1,457,000 after purchasing an additional 3,405 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.